CD19 and COVID-19: In this study, we described the COVID‐19 related details of R/R B‐cell lymphoma patients who received CD19 targeted CAR‐T heretofore in five cellular immunotherapy centers in China during the omicron wave, we found that only six patients (3.9%) suffered from severe COVID‐19, and three patients (1.9%) died from COVID‐19 infection or related complications in 3 months following‐up.